RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, midsized, full-service contract research organization (CRO), announced today that Gary Fishbein, MD, MPH, is its new executive medical director and medical lead for oncology.
Fishbein joins as the company continues to expand its oncology franchise and engage a growing number of small to midsized biotech and pharmaceutical organizations seeking the specialized expertise, personalized attention, and global infrastructure necessary to conduct complex oncology studies. Additional recent executive additions to the expanding Worldwide oncology franchise include Clare Wallis as senior vice president, oncology, and Emile Youssef, MD, PhD, as vice president, oncology scientific solutions.
Fishbein was selected by Worldwide for his achievements in oncology spanning all phases of drug development and tumor types, as well as for his personalized approach to client success.
“Following the close of a highly successful year for our oncology business, we continue to invest in building a deep bench of dedicated oncology experts who are well-versed in providing medical and scientific oversight on all aspects of even the most challenging studies,” said Peter Benton, president and chief operating officer, Worldwide Clinical Trials. “Dr. Fishbein is a board-certified oncologist with more than 20 years of experience in oncology treatment and research, clinical plan development, and clinical trial design, and I know our customers will appreciate the extraordinary access they will have to him.”
Before joining Worldwide, Fishbein served as senior director, Medical Affairs, for ICON, plc. Prior to that, he served in medical director leadership roles for PharmaNet (acquired by inVentiv Health, now Syneos Health) and the Janssen Pharmaceutical Companies of Johnson & Johnson.
A member of the American Society of Clinical Oncology, Fishbein has lectured, authored, and co-authored on such indications as T-cell lymphoma, adolescent melanoma, pancreatic cancer, metastatic breast cancer, systemic amyloidosis, acute myeloid leukemia, Hodgkin lymphoma and hepatocellular carcinoma.
Benton continued, “Great companies are distinguished by exceptional people. As we aspire to be the world’s best midsized CRO, we couldn’t be more fortunate to have the remarkable caliber of talent joining our expanding team.”
“I am thrilled to join this growing team. I’ve been impressed by Worldwide’s nimble, adaptive approach and the extensive experience this dedicated team has in overcoming the complexities of oncology trials. This is exactly what biopharma and biotech are searching for right now and what makes Worldwide stand out as an industry leader,” said Fishbein.
Fishbein earned a BA in chemistry from Haverford College and a MD from Thomas Jefferson University. He completed his clinical fellowship in medical oncology and hematology at the University of Maryland Marlene and Stewart Greenebaum Cancer Center and earned an MPH from Drexel University.
About Worldwide Clinical Trials
Worldwide Clinical Trials employs 2,000+ professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia-Pacific. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval, and real-world evidence, we provide world-class, full-service drug development services.
With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology, and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit www.worldwide.com.
